NCT02762084 2020-07-23Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome PatientsPellePharm, Inc.Phase 2 Completed17 enrolled 22 charts